Angelo Gordon & Co’s DexCom DXCM Stock Holding History

Angelo Gordon & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,600	Closed	-$2.9M	–	244
2021 Q4	$2.9M	Buy	+21,600	New	+$3.1M	0.27%	47

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Angelo Gordon & Co's DXCM Position: Q1 2022 in Review

Angelo Gordon & Co sold out of DexCom (DXCM) in Q1 2022, closing a stake of 21,600 shares — an estimated $2.9M sold.

Angelo Gordon & Co first reported a position in DXCM in Q4 2021 and held it in 1 quarter. The position peaked at $2.9M in Q4 2021. 861 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

Angelo Gordon & Co reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
Angelo Gordon & Co sold 21,600 DexCom shares in Q1 2022, an estimated $2.9M.
Angelo Gordon & Co first reported a position in DexCom in Q4 2021 and held it in 1 quarter.
Angelo Gordon & Co's DexCom position peaked at $2.9M in Q4 2021.
861 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Angelo Gordon & Co's 13F filing for Q1 2022, filed 16 May 2022.